Compare HQ & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HQ | SGP |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | Singapore | United States |
| Employees | 44 | 65 |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.7M | 650.9M |
| IPO Year | N/A | N/A |
| Metric | HQ | SGP |
|---|---|---|
| Price | $22.22 | $19.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | ★ 1.3M | 169.0K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.29 | $17.06 |
| 52 Week High | $45.00 | $30.56 |
| Indicator | HQ | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 51.36 | 48.40 |
| Support Level | $21.30 | $17.74 |
| Resistance Level | $45.00 | $20.25 |
| Average True Range (ATR) | 3.52 | 1.86 |
| MACD | -0.90 | 0.07 |
| Stochastic Oscillator | 25.11 | 28.90 |
Horizon Quantum Holdings Ltd is building software infrastructure to make quantum computers accessible to commercial enterprises and hardware providers. By bridging the gap between hardware and applications, the company seeks to equip developers, researchers, and enterprises with the quantum software infrastructure needed to solve real-world problems. The company is developing tools that can automatically accelerate code written for conventional computers on quantum computers.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.